S&P 500 5,432.10 ▲ +0.62% DOW 39,872.4 ▲ +0.31% NASDAQ 17,203.9 ▼ -0.18% 10Y YLD 4.28% ▲ +0.04 CRUDE $78.62 ▼ -1.02% BTC $61,204 ▲ +2.14% EUR/USD 1.0812 ▼ -0.09% GOLD $2,341.5 ▲ +0.47% S&P 500 5,432.10 ▲ +0.62% DOW 39,872.4 ▲ +0.31% NASDAQ 17,203.9 ▼ -0.18% 10Y YLD 4.28% ▲ +0.04 CRUDE $78.62 ▼ -1.02% BTC $61,204 ▲ +2.14% EUR/USD 1.0812 ▼ -0.09% GOLD $2,341.5 ▲ +0.47%
Business And Startup

Why global MedTech investors are eyeing this 350-acre park near Delhi

YEIDA additional CEO Shailendra Bhatia said the Sector 28 medical device park near Noida has already allotted 120 industrial plots and drawn construction from over 20 companies.

India’s push to build a domestic medical device manufacturing base is taking shape on a 350-acre site in Sector 28 of the Yamuna Expressway Industrial Development Authority (YEIDA) region, just outside Delhi-NCR. Speaking at a MedTech Investors’ Meet at India Expo Mart on Thursday, YEIDA additional CEO Shailendra Bhatia said the Authority has already allotted 120 industrial plots, with more than 20 companies already under construction on their manufacturing units.

Bhatia called the upcoming site a ‘major manufacturing hub’ intended to give north India a complete, end-to-end MedTech ecosystem rather than scattered production capacity.

Location is central to the pitch: the park lies just 3km from the under-construction Noida International Airport, positioning it to reach both domestic buyers and export markets once air connectivity comes online.

To lower the cost of entry for manufacturers, the park will house shared scientific and infrastructural resources, including rapid prototyping capability, artificial intelligence laboratories and a common warehouse, which Bhatia said would reduce production costs and support faster product development across companies based there.

The project also carries institutional weight, with IIT Delhi, IIT Kanpur, Invest UP and the Export Promotion Council providing academic and institutional support to firms at the site. Companies setting up units can additionally access a capital interest subsidy, stamp duty exemption, skill development support, quality certification assistance and marketing support.

Bhatia said investor interest so far spans radiology and imaging, implants, in-vitro diagnostics, anaesthesia and respiratory devices, and cardiology and cancer care, suggesting the park could serve a wide cross-section of India’s medical device needs rather than a single device category.

Image: Wikimedia Commons/by Lexington Medical, Inc.

Leave a Reply

Your email address will not be published. Required fields are marked *